Ivermectin for Covid-19

Discussion of scholar papers published until end of June and beginning of July, 2020, on Ivermectin, and of news that we can find about its use for Covid-19. A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedRχiv, which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19. From news, we consider in particular the case of Iquitos, capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably. The formulation of ivermectin used in Peru is also discussed, in particular that of the oral solution disclosed by the Peruvian Government. A section about updating (8 July) is added to the discussion. We report also the preprint posted on 8 July in MedRχiv, showing the result of a clinical trial. The preprint tells in the conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospital stay.Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19